2025
Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer.
Wang X, Lee D, Yang S, Li Y, Soulos P, Gross C, Wang S, Chiang A. Molecular Biomarker Testing Patterns and Turnaround Time in US Patients With Advanced Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2025, 1-7. PMID: 41072474, DOI: 10.6004/jnccn.2025.7063.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerLong test turnaround timesNon-small cell lung cancerCell lung cancerRetrospective cohort studyTest turnaround timeNext-generation sequencingTargeted therapyClinical outcomesAssociated with worse median progression-free survivalLung cancerUS patientsElectronic health record-derivedMedian progression-free survivalRetrospective cohort study of patientsNontarget treatmentCohort study of patientsProgression-free survivalTargetable genomic alterationsFirst-line treatmentHistory of smokingStudy of patientsNGS useEGFR testingNontargeted therapiesAssociation between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 PMID: 40670211, DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchSmoldering Multiple MyelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesBiomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsAdoption of Broad Genomic Profiling in Patients With Cancer
Wang X, Rothen J, Huang S, Long J, Soulos P, Goldberg S, Mamtani R, Presley C, Kunst N, Ma S, Wang S, Gross C, Dinan M. Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncology 2025, 11: 666-668. PMID: 40244595, PMCID: PMC12006912, DOI: 10.1001/jamaoncol.2025.0499.Peer-Reviewed Original ResearchRisk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors.
Kwaramba T, Westvold S, Long J, Hyslop T, Silber A, Lustberg M, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Dinan M. Risk and predictors of late second primary malignancies in long-term breast, prostate, colon, and rectal cancer survivors. Journal Of Clinical Oncology 2025, 43: 1642-1642. DOI: 10.1200/jco.2025.43.16_suppl.1642.Peer-Reviewed Original ResearchSurvivors of breastRectal cancer survivorsCancer survivorsYears post-diagnosisPost-diagnosisOlder survivorsScreen-detectedSEER-MedicareLong-term cancer survivorsNon-screened cancersLong-term breastStage I-III cancerProstate cancer survivorsIndex cancer diagnosisContinuous Medicare Parts ASEER-Medicare dataModifiable risk factorsMedicare Part ADiagnosis of SPMSurvivorship careSEER-Medicare databaseSurvivorship cohortScreening guidelinesAssociated with shorter timeIndex cancerHigh-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
Fiala M, Ji M, Slade M, Huber J, Shih Y, Wang M, Colditz G, Wang S, Vij R, Chang S. High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma. JCO Oncology Practice 2025, op2400978. PMID: 40354593, PMCID: PMC12354019, DOI: 10.1200/op-24-00978.Peer-Reviewed Original ResearchStem-cell transplantationMultiple myelomaTreatment initiationHigh-deductible health plan enrollmentHigh-deductible health plansTransplant receiptShorter time to treatment initiationTime to treatment initiationOOP costsHealth Insurance DatabaseAssociated with delayStatistically significant differenceHealth plansPlan enrolleesOut-of-pocket health care costsYounger patientsOut-of-pocket (OOP) costsCox regressionPrimary outcomeMultivariate analysisSecondary outcomesInsurance databasePatientsTotal health careHealth care costsProstate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer
Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Kunst N, Wang S, Ma X, Gross C, Leapman M, Karnes R. Prostate-Specific Membrane Antigen Imaging Findings and Subsequent Clinical Management Among Patients With Biochemically Recurrent Prostate Cancer. JU Open Plus 2025, 3 DOI: 10.1097/ju9.0000000000000278.Peer-Reviewed Original ResearchMetastasis-directed therapyPSMA PET findingsPSMA-PETBiochemical recurrencePSA levelsDistant metastasisProstate cancerLocal therapyProstate-specific membrane antigen positron emission tomographyClinical managementBiochemically recurrent prostate cancerIdentification of distant metastasesNegative PSMA-PETRecurrent prostate cancerRegional nodal diseasePositron emission tomographyNodal diseaseLocal recurrenceInitial therapySystemic therapyTreatment initiationClinical outcomesImaging findingsMetastasisTreatment choicePersonalized frailty risk assessment in long-term survivors of colorectal cancer.
Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.Peer-Reviewed Original ResearchRectal cancer survivorsCancer survivorsElixhauser Comorbidity IndexLong-term survivors of colorectal cancerSurvivors of colorectal cancerClinical prediction modelStage I-III colonCancer diagnosisGastrointestinal cancer survivorsYear 4Area-level povertyAssociated with reduced qualityRisk of frailtyProportion of residentsOnset of frailtyPredictors of frailtyFederal poverty lineIncreased risk of deathAdministrative claims codesSurvivorship managementRisk of deathRetrospective cohort studyAssociated with shorter timePatient raceSevere frailty
2024
Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Li Y, Hsu S, Wang R, Theprungsirikul P, Neparidze N, Chang S, Wang S. Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e222-e231. PMID: 39730300, PMCID: PMC11911095, DOI: 10.1016/j.clml.2024.12.006.Peer-Reviewed Original ResearchProgression to MMMultiple myelomaNewcastle-Ottawa ScaleMonoclonal gammopathyRisk of progression to MMIncreased riskProgression to multiple myelomaRisk estimatesHigher Body Mass IndexPre-malignant conditionBody mass indexRandom-effects modelMass indexCohort studyPatient characteristicsFemale sexMale genderMethodological qualityNewcastle-OttawaBlack raceRisk ratioMGUSRisk factorsPublication biasSystematic reviewLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed TreatmentDisease courseAsymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.
Ji M, Shih Y, Huber J, Wang M, Feuer E, Etzioni R, Wang S, Chang S. Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 1690-1697. PMID: 39106151, PMCID: PMC11611677, DOI: 10.1158/1055-9965.epi-24-0490.Peer-Reviewed Original ResearchNHB populationNHW populationsPreclinical durationNon-HispanicNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyNutrition Examination SurveyPopulation-based screeningMultiple myelomaNHW counterpartsExamination SurveyMGUS prevalenceMonoclonal gammopathyIncidence rateNHWNatural history of MMMM incidenceNHBIncidence of monoclonal gammopathyCumulative riskHistory of MMMGUS to MMPopulation age distributionEpidemiologyAsymptomatic incidenceTreatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma
Fiala M, Ji M, Shih Y, Huber J, Wang M, Johnson K, Gasoyan H, Wang R, Colditz G, Wang S, Chang S. Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: 109-115. PMID: 39209567, PMCID: PMC12179426, DOI: 10.1016/j.clml.2024.07.017.Peer-Reviewed Original ResearchStem cell transplantationCell transplantationMyeloma therapyMultiple myelomaContinuous enrollmentAssociated with early detectionMulti-State Medicaid DatabaseMultivariate logistic regressionMyeloma patientsSolid tumorsHigh medical needMyeloma treatmentHematological cancersMyelomaPatientsMedicaid databaseClaims-based datasetScreening testAcute medical eventsLogistic regressionEarly detectionDiscontinuous enrollmentMedical needContinuous Medicaid coverageCancer diagnosisPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyFrom criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
Ji M, Wang M, Shih Y, Huber J, Fiala M, Wang R, Sanfilippo K, Thomas T, Wang S, Schoen M, Chang S. From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity. Journal Of Clinical Oncology 2024, 42: 7556-7556. DOI: 10.1200/jco.2024.42.16_suppl.7556.Peer-Reviewed Original ResearchInternational Myeloma Working GroupMagnetic resonance imagingFree light chainsMGUS patientsMM casesActive MMDiagnostic criteriaMultiple myelomaPlasma cellsClonal bone marrow plasma cellsComputed tomographyOld criteriaPositron emission tomography-CTBone marrow plasma cellsSerum free light chainsSLiM-CRAB criteriaProgression to MMClonal plasma cellsMarrow plasma cellsMM patient outcomePlasma cell malignancyAggressive diagnostic strategyInternational Classification of Diseases (ICD)-9/10 codesCRAB symptomsPositive detection ratePD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission Tomography ImagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply